Press Releases View all 10 hits
Press Releases • May 09, 2014 09:38 GMT
A presentation on the importance of global viral load monitoring to contain the HIV pandemic.
Press Releases • Apr 11, 2014 06:00 GMT
Press Releases • Nov 15, 2013 09:29 GMT
Leading Swedish HIV diagnostic company Cavidi today announced the signing of a license agreement for technology in the detection of CD4 T-cell levels. The CD4 test, developed by the Burnet Institute in Melbourne, Australia, and a long time partner to Cavidi, can be added to Cavidi’s Viral Load test on the next generation automated bench top instrument.
News View all 20 hits
News • Feb 04, 2015 14:21 GMT
News • Oct 16, 2014 09:12 GMT
Cavidi is working on making diagnostics more accessible. Since Cavidi was founded the company has tried to get closer to the HIV-infected population in the parts of the world that are most affected – that is to say a large part of the developing world. This is being done by taking the lab process out into the field, close to the millions of people who live with HIV.
Blog posts 4 hits
Blog posts • Nov 28, 2013 09:50 GMT
Each year World Aids Day helps raise awareness around the world. It’s also a time for everyone involved in the fight against HIV to step back and assess our progress. Looking at the HIV community as a whole and Cavidi in particular, I can say it’s been a good year overall. We have seen great progress in the treatment of HIV worldwide.
Blog posts • Jul 23, 2012 10:30 GMT
There are around 370,000 new infant infections worldwide each year. A significant number of these children will die if they are not diagnosed early and started on antiretroviral drugs (ARVs). The problem is not the lack of ARVs as much as a lack of proper HIV early infant diagnostics (EID). Recent reports indicate that RT-technology may be an answer to improved access to (EID).
Blog posts • Oct 13, 2011 08:52 GMT
Although the North American and Western European experience has historically been with HIV-1 group M subtype B virus, this is changing rapidly as migrants and refugees from developing countries with non-B subtype infections now present for care in the developed world, and travelers to developing countries acquire non-B subtype infection abroad and present for care at home.
Images 4 hits
Videos 2 hits
Documents 3 hits
Documents • Sep 09, 2013 10:48 GMT
Routine use of viral load testing makes business sense: it will save money on drugs with effective monitoring of patients. MSF identifies the needs of a solution in a wish list on p23. This is the market opportunity that Cavidi is seeking to address with our new platform meeting requirements that MSF have identified for laboratory-based tests. Cavidi ref on p 5,20,21,23,30,and 31.